After a strong show in Q1, momentum accelerated in Q2 driven by the solid demand for COVID-19 testing solutions, particularly RNA extraction kits, third-party reagents and cartridges for QIAStat-Dx. However, momentum was partly offset by weaker customer demand trends in other product areas due to lower patient traffic in hospitals and the resulting decline in routine testing. Higher sales also led to a higher than expected increase in earnings. Unsurprisingly, rival bioMerieux also witnessed
10 Jul 2020
Robust Q2 led by COVID-19 testing solutions
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Robust Q2 led by COVID-19 testing solutions
After a strong show in Q1, momentum accelerated in Q2 driven by the solid demand for COVID-19 testing solutions, particularly RNA extraction kits, third-party reagents and cartridges for QIAStat-Dx. However, momentum was partly offset by weaker customer demand trends in other product areas due to lower patient traffic in hospitals and the resulting decline in routine testing. Higher sales also led to a higher than expected increase in earnings. Unsurprisingly, rival bioMerieux also witnessed